MedTrace Logo

Surufatinib Renal Impairment Study

NCT04755088 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2022-11-03

No results posted yet for this study

Summary

An open-label, multicenter, single-dose, single-period, sequential study to assess the effect of moderate renal impairment on the pharmacokinetics of surufatinib.

Conditions

  • Renal Impairment

Interventions

DRUG

Surufatinib

Subjects to receive Surufatinib 300mg on Day 1

DRUG

Surufatinib

Subjects to receive Surufatinib 300mg on Day 1

Sponsors & Collaborators

  • Hutchison Medipharma Limited

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-12
Primary Completion
2021-08-21
Completion
2021-08-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04755088 on ClinicalTrials.gov